BTX may be used in the therapy of OAB
Wednesday, 26 November 2008 - As J. Wojtkiewicz et al. pointed out at the 8th Central European Meeting in Warsaw, Botulinum toxin of the A type (BTX) is able to modify not only the chemical phenotypes of cholinergic or sensory neurons, but also influence the kind of neurotransmitter substances synthesized by sensory...
Edited by: FGR
Showering and sunscreen do not affect overactive bladder topical gel
Tuesday, 25 November 2008- Absorption of oxybutynin chloride topical gel, an investigational therapy for overactive bladder, is not affected by showering or sunscreen use, according to data presented at the Society of Urologic Nurses and Associates annual conference held in Philadelphia, USA.
Three open-label,...
Edited by: JV
Morphologic MR with 3D spectroscopy MR is helpful in early PCa diagnosis
Monday, 24 November 2008- At the 8th EAU Central European Meeting S. Bak et al. compared morphologic MR with 3D spectroscopy MR. “We receive additional information about prostate cancer and we are able to localize prostate cancer more precisely. This method is helpful in early prostate cancer diagnosis. It is...
Edited by: FGR
ASRM symposium: session highlights on male reproductive toxicology
Friday, 21 November 2008 - At the recent 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM) held in San Francisco, USA, the plenary symposium on male reproduction and toxicology examined the increasing incidence of testicular cancer, cryptorchidism and hypospadias and reports of...
Edited by:JV
Higher risk of secondary cancers for PCa patients exposed to EBRT
Thursday, 20 November 2008 - Several previous reports addressed the effect of external-beam radiation therapy (EBRT) on the rate of secondary malignancies in patients with localized prostate cancer. Conflicting results were also reported. Canadian researchers have addressed the association between EBRT exposure and...
Edited by: JV
ESU holds successful 1st Masterclass on Female and Functional Reconstructive Urology
Wednesday, 19 November 2008 - The comprehensive programme of the 1st Masterclass on Female and Functional Reconstructive Urology organised by the European School of Urology (ESU) elicited positive responses from the participants who all welcomed the detailed lectures and discussions.
A selected group of 21...
By: Joel Vega
Aspirin usage linked to lower PSA levels in men
Tuesday, 18 November 2008 - The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower PSA levels, especially among men with prostate cancer, say researchers at Vanderbilt University in the US.
This large analysis known as the Nashville Men's Health Study...
Edited by: JV
Validation of nomogram for predicting pathological stage of prostate cancer
Monday, 17 November 2008 - Researchers Otakar Capoun, Marek Babjuk, et al., conducted a study to validate the Memorial Sloan-Kettering Cancer Centre (MSKCC) preoperative nomogram for predicting the pathological stage of prostate cancer (PCa) after radical prostatectomy in patients in the Czech Republic.
In...
Edited by: JV
Phase 2 studies show benefit of investigational BPH drug NX-1207
Friday, 14 November 2008 - Nymox Pharmaceutical Corporation’s investigational benign prostatic hyperplasia (BPH) drug NX-1207 provided significant improvement in urinary symptoms for men afflicted with diseases, according to recently completed phase 2 studies conducted in the US.
Dr. Barrett Cowan, who has...
Edited by: JV/PR
Major risk factors for nocturia: a systematic, population-based investigation
Thursday, 13 November 2008 - Nocturia is poorly understood; it often persists after treatment. Dr. Kari Tikkinen, et al. conducted a study aimed to assess the major risk factors for nocturia (defined as >/- 2 voids/night using DAN-PSS and AUA-SI). The authors presented their abstract, co-winner of the second...
Edited by: JV
